http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update
-
VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update
-
VolitionRx Limited Schedules Third Quarter 2018 Earnings Conference Call and Business Update
-
VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics
-
VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board
-
VolitionRx Limited to Attend Multiple Conferences in September
-
VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update
-
Volitionrx (VNRX) Says Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
-
Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
-
VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study
-
VolitionRx Announces $9 Million Private Placement
-
VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update
-
VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
-
Volition Extends Global Reach of its Clinical Trial Program
-
Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region
-
VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018
-
VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update
-
VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits
-
VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update
-
VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock
-
Volitionrx Limited (VNRX) Prices 3.5M Common Stock Offeirng at $2.40/Share
-
VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock
-
Volitionrx Limited (VNRX) to Offer Common Stock
-
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
-
VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board
-
VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update
-
VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update
-
VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer
-
VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.
-
VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone
-
VolitionRx Limited to Attend Conferences in December
-
Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies
-
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update
-
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update
-
VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits
-
VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding
-
VolitionRx Announces its European Colorectal Cancer Strategy
-
VolitionRx to Attend Two Major Conferences in Asia
-
Volition Granted Four Additional Patents
-
VolitionRx Limited to Attend Multiple Conferences in September
-
Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers
-
VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update
-
VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update
-
VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute
-
Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Ins
-
Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress
-
VolitionRx Limited Corrects an Earlier Announcement
-
VolitionRx Limited to Present at Multiple Investor Conferences in June
-
A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays
-
VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

